Metaglidasen is a synthetic pharmaceutical research compound belonging to the selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator class. It was developed as an investigational insulin-sensitizing compound and is also known by the development code MK-185FA and the designation MBX-102. MEDIOCON INC provides Metaglidasen for qualified pharmaceutical research, analytical development and specialized research requirements.
Metaglidasen is chemically known as 2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetic acid. It has the molecular formula C₁₅H₁₀ClF₃O₃, CAS number 4687-08-5, and molecular weight approximately 330.69 g/mol. PubChem identifies the compound as Metaglidasen and records its chemical structure, synonyms and molecular information.
Metaglidasen is a fibrate-like PPARγ modulator that was investigated for metabolic disorders, particularly type 2 diabetes and insulin resistance. Scientific literature describes it as a selective PPARγ modulator and discusses its pharmacological activity in relation to glucose and lipid metabolism.
The compound is a carboxylic acid containing a 4-chlorophenyl group and a 3-trifluoromethylphenoxy group. It has one stereogenic center and has been studied as a racemic mixture as well as through individual stereoisomers. Research literature reports stereochemistry-dependent biological activity for the corresponding enantiomers.
Research-supplier data report Metaglidasen as a solid powder with purity >98% or according to the applicable Certificate of Analysis (COA). MedKoo also reports storage under dry, dark conditions, with 0–4°C for short-term storage and −20°C for long-term storage.
MEDIOCON INC supplies Metaglidasen for qualified research and pharmaceutical development requirements, with applicable product documentation such as Certificate of Analysis (COA), MSDS/SDS and technical specifications according to the material specification.
Because Metaglidasen is an investigational pharmaceutical compound rather than a currently established pharmacopoeial API, its release specifications should be based on the applicable validated manufacturer specification and COA rather than an unsupported USP/BP/EP claim.
| Parameter | Specification |
|---|---|
| Appearance | Solid Powder |
| Identification | IR & HPLC Complies |
| Assay (HPLC) | >98.0% by HPLC |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.5% |
| Water Content | NMT 1.0% |
| Melting Point | 98–100°C |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Metaglidasen API Manufacturer & Supplier in India | MEDIOCON INC (CAS 4687-08-5) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Metaglidasen API Manufacturer & Supplier in India | MEDIOCON INC is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.
Export Markets
Quality & Compliance